The herpesvirus entry mediator C (HveC), previously known as poliovirus receptor-related protein 1 (PRR1), and the herpesvirus Ig-like receptor (HIgR) are the bona fide receptors employed by herpes simplex virus-1 and -2 (HSV-1 and -2) for entry into the human cell lines most frequently used in HSV studies. They share an identical ectodomain made of one V and two C2 domains and differ in transmembrane and cytoplasmic regions. Expression of their mRNA in the human nervous system suggests possible usage of these receptors in humans in the path of neuron infection by HSV. Glycoprotein D (gD) is the virion component that mediates HSV-1 entry into cells by interaction with cellular receptors. We report on the identification of the V domain of HIgR͞PRR1 as a major functional region in HSV-1 entry by several approaches. First, the epitope recognized by mAb R1.302 to HIgR͞PRR1, capable of inhibiting infection, was mapped to the V domain. Second, a soluble form of HIgR͞ PRR1 consisting of the single V domain competed with cell-bound full-length receptor and blocked virion infectivity. Third, the V domain was sufficient to mediate HSV entry, as an engineered form of PRR1 in which the two C2 domains were deleted and the V domain was retained and fused to its transmembrane and cytoplasmic regions was still able to confer susceptibility, although at reduced efficiency relative to full-length receptor. Consistently, transfer of the V domain of HIgR͞PRR1 to a functionally inactive structural homologue generated a chimeric receptor with virus-entry activity. Finally, the single V domain was sufficient for in vitro physical interaction with gD. The in vitro binding was specific as it was competed both by antibodies to the receptor and by a mAb to gD with potent neutralizing activity for HSV-1 infectivity.
The receptors that mediate herpes simplex virus (HSV) entry into cells have remained elusive for a long time for several reasons. Cell lines lacking receptors are very rare, hampering a genetic approach to the search of the receptors. The virus appears to be able to use alternative receptors (1) . Cellular proteins that are able to act as mediators of virus entry when transfected in cells that do not express any other suitable receptor have such a narrow distribution that their actual usage is limited to very specialized cell types. This appears to be the case for herpesvirus entry mediator A (HveA), previously designated HVEM (for herpesvirus entry mediator), which appears to be expressed and functional only in T lymphocytes (2) . Recently, the bona fide receptors that mediate HSV-1 entry into human cells were identified as a cluster of molecules belonging to the IgG superfamily (3) (4) (5) . They have a common structure defined by six conserved cysteines in the ectodomain, which form three domains, one V-like and two C2-like. There are three members known to date: the herpesvirus entry mediator C (HveC) (3), previously known as PRR1, for poliovirus receptor-related protein 1 (6) , and HIgR, for herpesvirus Ig-like receptor (5) , both of which enable entry of all HSV-1 and -2 strains tested, and HveB (or PRR2) (7) , which enables entry of a subset of HSV strains, namely HSV-2 and some HSV-1 gD mutants, but not wild-type HSV-1 strains (4). HIgR and PRR1(HveC) share an identical ectodomain, differ in the transmembrane and cytoplasmic regions, and appear to be splice-variant isoforms (5) . Evidence that they can be considered as the bona fide receptors that mediate HSV-1 entry into the most frequently used human cell lines rested on the expression of HIgR͞PRR1 proteins in cell lines like HEp-2, HeLa, human fibroblasts, etc., as detected by reactivity to mAb R1.302 to PRR1, and on the ability of the same antibody to block HSV-1 infection in these cells (5) . The high level of mRNA expression in samples from nervous system suggests possible usage in humans in the path of neuron infection by HSV (5) . The finding that two isoforms-HIgR and PRR1(HveC)-sharing the ectodomain can both mediate HSV entry mapped the functional region of the receptors to their ectodomain (5) .
At least four virion glycoproteins, gB, gD, and the heterodimer gH͞gL, participate in HSV-1 entry into cells (8) (9) (10) (11) . Work of the past decade has pointed to gD as the virion component that interacts with cellular receptor(s). The initial observation that expression of gD rendered cells resistant to infection led to the proposal that gD sequesters a putative receptor able to bind the glycoprotein (12) . The notion subsequently was strengthened by the findings that incubation of gD-expressing cells with antibodies to gD released the block (1, 13) , that viral unrestricted mutants able to overcome the gD-mediated block carry mutations in gD (1, 13, 14) , that antiidiotypic antibodies mimicking gD could bind the surface of commonly used cell lines and blocked virus infectivity and cell-to-cell spread of virus (15) , that cells susceptible to HSV infection were able to bind gD in a saturable manner (16) , and that soluble forms of gD inhibited virion infectivity (16, 17) . No such evidence for involvement of cellular receptors exists for the other glycoproteins, gB and gH͞gL.
HSV-1 penetration into cells occurs through a pHindependent fusion event (18, 19) . The molecular mechanisms underlying this process remain, in part, obscure, and a model is still lacking that shows how the interaction of gD with its cellular receptor triggers the fusion of the virion envelope with the plasma membrane and recruits the other virion glycoproteins. The aim of the present work was to identify regions of HIgR͞PRR1 that are functional in HSV-1 entry and interact with HSV-1 gD. We demonstrate that (i) a major functional region of HIgR͞PRR1 with HSV-1 entry activity resides in the V domain of the molecules; (ii) when anchored to cell membrane either through its own transmembrane and cytoplasmic domains, or through transplantation to a structurally related, functionally inactive molecule, the V domain was sufficient to mediate HSV-1 entry into cells, although the collapsed receptor displayed a reduced efficiency compared with full-length molecules; and (iii) the single V domain was sufficient for binding to gD in vitro in a specific fashion, providing evidence for a direct physical interaction between the major functional region of HIgR͞PRR1 in virus entry and its viral ligand, gD.
MATERIALS AND METHODS
Cells and Viruses. Cells were grown in DMEM supplemented with 5% fetal calf serum. HIgR͞cl 11, PRR1͞cl 5, and V-TM(PRR1)͞Q were obtained by lipofectamine transfection of J1.1-2 cells (5) with pCF18 (HIgR), pLX1.12 (PRR1), or pCDTMR1V.3 and neomycin G418 selection. The HSV-1 recombinant R8102, which carries the lacZ gene under the control of the ␣27 promoter inserted between U L 3 and U L 4 genes, was a gift of B. Roizman and will be described elsewhere. Pelleted extracellular virions were used in all experiments. Infectivity of R8102 was assayed as described (2) .
Antibodies. mAb R1.302 to PRR1 and mAb 30 to gD were described (1, 20) . mAb HD1 (21) to gD was from Goodwin Institute (Plantation, FL). Construction of V-TM(PRR1) and V(HIgR)-PVR␣ Transmembrane Receptors. The V domain of HIgR was amplified with PRR1V5 (TAAT AAGC TTAT GGCT CGGA TGGG GCTT GCGG GC) and PRR1V3(GGTG TAGG GGAA TTCC ATCA CCGT GAGA TTG). The transmembrane and intracytoplasmic region was amplified by using primers PRR1IC5 (CAAT CTCA CGGT GATG GAAT TCCC CTAC ACC) and PRR1IC3 (ATTA GGAT CCCT ACAC GTAC CACT CCTT CTTG G). Both PCR products were mixed in a second PCR to get the final cDNA with primers PRR1V5 and PRR1IC3 (23) , cloned in the BamHI-HindIII sites of pcDNA3. For the chimeric receptor V(HIgR)-PVR␣, the V domain was amplified with primers PRR1V5 and R1VRV3 (GTGT TCTG GGGC TTGG CCAT CACC GTGA GATT G). The two C domains and transmembrane and intracytoplasmic regions of PVR␣ were amplified with primers R1VRCC5 (CAAT CTCA CGGT GATG GCCA AGCC CCAG AACA C) and R1VRCC3 (GTTA GGAT CCTC ACCT TGTG CCCT CTGT CTG). The 1,253-bp cDNA fragment was cloned in BamHI͞HindIII sites of the pcDNA3.
Sandwich ELISA for the Soluble Forms of HIgR͞PRR1, sVCC(HIgR)-Fc, and sV(HIgR)-Fc. sVCC(HIgR)-Fc and sV(HIgR)-Fc were bound to microwells by means of antihIgG-Fc (Sigma) and reacted with biotinylated mAb R1.302, followed by streptavidin-peroxidase and One Step ABTS (Pierce).
Competition by sVCC(HIgR)-Fc and sV(HIgR)-Fc on HIgRMediated HSV-1 Infectivity. Aliquots of R8102 were reacted with sVCC(HIgR)-Fc, sV(HIgR)-Fc, or CTLA4-Fc for 1 h at 37°C and absorbed to cells for 2 h at 4°C. Virus was removed. Cells were overlaid with medium containing the sVCC(HIgR)-Fc and sV(HIgR)-Fc at the same concentrations used in the inoculum and incubated for 16 h at 37°C. ␤-Galactosidase (␤-gal) was assayed as described (2) .
Competition of HSV-1 Infectivity by Soluble gD. HIgR͞cl 11 cells in 96-well plates were preincubated for 2 h at 4°C with gD-1(⌬290-299t) (24) . Viral inoculum in 7.5 l was added for 90 min at 4°C, removed, and cells were overlaid with DMEM containing glycoprotein. Infection was monitored as above.
In Vitro Binding of gD to Soluble Forms of HIgR͞PRR1 by ELISA. gD was purified to homogeneity from HSV-1-infected BHK cells by affinity chromatography to mAb 30 (1) 
RESULTS

Construction and Purification of Soluble Forms of HIgR͞ PRR1 and of Human Poliovirus Receptor-␣ (hPVR␣).
Two soluble forms of HIgR͞PRR1 and one of hPVR␣ were constructed. In sVCC(HIgR)-Fc, the three domains (one V and two C2) that constitute the ectodomain of HIgR and of PRR1 were fused to the Fc domain of human IgG1. In sV(HIgR)-Fc, the single V domain of HIgR͞PRR1 was fused to IgG Fc. In sVCC(PVR)-Fc, the ectodomain of hPVR␣ was fused to the IgG1 Fc. Schematic representation is shown in Fig. 1 . COS1 cells were transfected with the plasmid DNAs, and the soluble receptors were purified from the culture medium by affinity chromatography to protein A. The purity of the protein preparations was checked by silver staining of proteins separated by SDS͞PAGE and by immunoblotting with a peroxidase-labeled antibody directed to the human Fc portion of IgG (data not shown). Under reducing conditions, the apparent M r of purified sVCC(HIgR)-Fc and sV(HIgR)-Fc was 70,000 and 45,000, respectively, whereas the predicted M r values were 59,600 and 38,300, possibly reflecting glycosylation of some of the predicted glycosylation sites present in the ectodomain of HIgR͞PRR1. The V domain, as defined here and below, comprises the N-terminal 114 residues, after cleavage of the predicted signal sequence.
The HIgR͞PRR1 Epitope Recognized by mAb R1.302 Resides in the V Domain. mAb R1.302 is capable of blocking HSV-1 infectivity in hamster cell lines that express either HIgR or PRR1 from transfected plasmids as well as in human cell lines such as HEp-2, HeLa, human fibroblasts, U937, TF-1, etc., which express either one or both isoforms (5) . As HIgR and PRR1 share the ectodomain, the epitope recognized by mAb R1.302 must reside in the ectodomain of the molecules. Fig. 2 shows that the epitope recognized by mAb R1.302 resides in the V domain of the HIgR͞PRR1. In a sandwich To ascertain whether the V domain of HIgR͞ PRR1 was sufficient to mediate HSV-1 entry into cells, a construct was generated in which the two C2 domains of PRR1 were deleted and the single V domain was fused directly to its transmembrane-cytoplasmic domains, designated V-TM-(PRR1). The J1.1-2 cells, resistant to HSV infection because of lack of suitable receptors (5), were transfected with the plasmid DNA, subjected to neomycin G418 selection for 2 weeks, and assayed for susceptibility to R8102. R1.302, which is capable of inhibiting infection and whose reactive epitope maps to the V domain (Fig. 4B) . The number of cells acquiring susceptibility increased when cells were infected at higher moltiplicity of infection (100 plaque-forming units per cell) (data not shown). The number of cells acquiring susceptibility was much lower in cultures expressing V-TM(PRR1) than in cultures expressing the full-length HIgR or PRR1. This may be due to either a lower extent of expression of V-TM(PRR1) relative to the full-length molecules or a lower efficiency of the truncated molecule in conferring susceptibility to infection. To discriminate between these two possibilities the extent of expression was compared in V-TM-(PRR1)-and HIgR-transfected cells by immunofluorescence with mAb R1.302. The number of fluorescent cells was found to be practically the same (data not shown), suggesting that the deleted version of PRR1 lacking the two C domains is less effective than the full-length counterpart in conferring susceptibility to HSV-1 infection. Parenthetically, the reactivity of mAb R1.302 to cells expressing the deleted and the full-length versions of HIgR͞PRR1 confirms that mAb R1.302 is directed to an epitope present in the V domain. Altogether, the results demonstrate that the V domain of HIgR͞PRR1 was sufficient to mediate HSV-1 entry into cells, although at reduced efficiency relative to the full-length receptor, and that susceptibility conferred by V-TM(PRR1) correlated specifically with the presence of the V domain.
To confirm this and to investigate the reasons for the lower efficiency of V-TM(PRR1), a second construct was generated in which the V domain of HIgR͞PRR1 was transferred to CC-transmembrane-cytoplasmic regions of hPVR␣. This receptor was chosen as acceptor of the HIgR͞PRR1 V domain because it has an overlapping structure to that of HIgR (6) but fails to mediate entry of any HSV-1 and -2 tested (3). Therefore, it represents the available receptor that is functionally inactive but structurally closer to HIgR͞PRR1. Fig. 4C shows that V(HIgR)-PVR␣ transfected into the resistant J1.1-2 cells conferred susceptibility to HSV-1 infection and had an efficiency comparable to that of full-length HIgR (compare Fig.  4 C and E) . Infectivity was abolished by exposure of cells expressing V(HIgR)-PVR␣ to mAb R1.302 (Fig. 4D) , demonstrating that the susceptibility acquired by V(HIgR)-PVR␣ was a result of transfer of the V domain of HIgR͞PRR1. The results confirm that the V domain of HIgR was sufficient to confer susceptibility and, in addition, suggest that the CC backbone of this cluster of molecules augments the virus entry activity located in the V domain and͞or participates in virus entry activity with other mechanisms, as noted in the Discussion.
Soluble gD Competes with HSV-1 Infectivity in Cells in Which HIgR Is the Only Available Receptor. Soluble forms of gD inhibit HSV-1 infectivity in Vero cells (16) . As the receptors employed by HSV in these cells have not yet been identified, the cellular protein binding gD required for the gD inhibitory effect is unknown. In HveA-transformed cells, gD blocked HSV-1 infectivity (26), consistent with the ability of gD to bind HveA (27) . Cells expressing HIgR or PRR1 acquire the ability to bind gD (5, 27) . In this series of experiments we verified whether soluble gD can compete with HSV-1 infectivity in cells in which HIgR was the only available receptor. HIgR͞cl 11 cells were preincubated with increasing amounts of a soluble recombinant form of gD [gD-1(⌬290-299t)] (24), or with fetuin, as a control, unrelated glycoprotein, and subsequently infected with R8102. Results in Fig. 5 show that gD inhibited R8102 infectivity in a dose-dependent manner, while fetuin had no significant effect. The experiment demonstrates that in cells where HIgR was the only available receptor, the binding of HIgR with gD was crucial for HSV-1 entry.
The Single V Domain Is Sufficient for Physical Interaction with gD. The above data demonstrate that a major region of HIgR͞PRR1 functional in HSV-1 entry resides in the V domain and that this domain is sufficient to mediate HSV-1 infectivity. gD binds to a soluble form of HveC(PRR1) containing the entire ectodomain (27) . Here we investigated whether the single V domain of HIgR͞PRR1 was sufficient for the physical interaction with gD. Fig. 6A ), was preincubated with increasing concentrations of IgG from mAb R1.302 to HIgR͞PRR1, or from mAb HD1, a mAb to HSV gD with potent neutralizing activity on HSV infectivity (21) and with the ability to compete with the binding of PRR1(HveC) to virions in vitro (27) , or with purified mouse IgGs, as control. As can be seen from Fig. 6B , both the mAb to HIgR and the neutralizing mAb HD1 to gD competed with the binding of gD to the soluble V domain of HIgR͞PRR1, demonstrating that the in vitro binding of the V domain to gD was highly specific. The results of these two assays indicate that the V domain of HIgR͞PRR1 was sufficient for specific binding to gD. The results confirm and extend the finding that the gD region recognized by HIgR͞PRR1 contains the antigenic site Ia (27, 28) .
DISCUSSION
To understand how the interaction of HSV-1 with HIgR or PRR1 leads to virus entry into the cell, it is necessary to obtain a detailed picture of the domains of HIgR͞PRR1 that are functional in HSV-1 entry and of the physical interaction between the functional domains and gD, the virion component engaged in virus entry. For many viruses and cognate receptor systems, genetic analyses coupled to demonstration of physical interaction between the two partner molecules provided a basis for unraveling this interaction. This paper shows that a major region of HIgR͞PRR1 with HSV-1 entry activity resides in the V domain. We show that (i) the V domain is a major determinant of HIgR͞PRR1 in mediating HSV-1 entry, (ii) the V domain anchored to cell membrane is sufficient to mediate HSV-1 entry into cells, and (iii) the single V domain is sufficient for the in vitro physical interaction with gD in a specific manner. It is convenient to discuss each issue separately.
The V Domain Is a Major Determinant of HIgR͞PRR1 in Mediating HSV-1 Entry. Evidence for this conclusion rests cumulatively on two series of experiments. First, the mAb R1.302 to HIgR͞PRR1, capable of inhibiting infection, reacted with an epitope mapped to the V domain of HIgR͞ PRR1. Second, a soluble form of the HIgR͞PRR1 containing the single V domain competed in a dose-dependent manner with full-length, cell-bound receptor and blocked virus infectivity. Thus, HIgR adds a new member to the list of Ig-like viral receptors whose major functional domains reside in the more external regions. The list includes PVR, the poliovirus receptor, ICAM, the rhinovirus receptor, and CD4, the HIV receptor (29) (30) (31) (32) (33) (34) (35) (36) . That the N-terminal domains carry functional regions is consistent with the view that, even in the folded molecules, these regions are located more externally and therefore are more likely to interact with the appropriate regions of the virions.
The V Domain Anchored to Cell Membrane Is Sufficient to Mediate HSV-1 Entry into Cells. This conclusion rests on two experiments. First, the receptor-deficient J1.1-2 cells resistant to HSV-1 infection were rendered susceptible when transfected with an engineered form of PRR1 in which the V domain and transmembrane and cytoplasmic regions were retained and fused together but the two C2 domains were deleted. Second, the V domain of HIgR͞PRR1 was transplanted to CC-transmembrane-cytoplasmic portion of hPVR␣, a structural homologue of HIgR and PRR1 not functional in HSV-1 and -2 entry, generating a chimeric receptor that acquired HSV-1 entry activity. As infectivity was abolished by neutralizing mAb R1.302 in both cases, the receptor activity resided in the V domain. We conclude that the V domain is sufficient to act as a receptor as long as it is anchored to the membrane by suitable transmembrane͞ cytoplasmic domains.
The Single V Domain Is Sufficient for the in Vitro Physical Interaction of HIgR͞PRR1 with gD. gD is a key component of the viral machinery essential for virus entry into susceptible cells, as outlined in the Introduction. Furthermore, gD can interact physically with full-length ectodomain of HveC(PRR1) (27) . It was of interest to determine whether the V domain, herein shown to encode a major region functional in HSV-1 entry, was sufficient for in vitro binding to gD, or whether other portions of the ectodomain would mediate this binding. Here we show that a soluble form of HIgR͞PRR1 consisting of the single V domain interacted physically with gD in an in vitro binding assay. The binding was specific as it was competed by mAbs to each partner with the ability to neutralize HSV infectivity. Thus, mAb R1.302 to HIgR͞PRR1 competed with the ability of gD to bind to the receptor. In a similar fashion, the mAb HD1 to gD with potent neutralizing activity on virion infectivity competed with the binding of gD to its receptor. It can be noted that mAb HD1 recognizes antigenic site Ia of gD, according to the classification of Cohen and Eisenberg (28) . The results further indicate that the gD region that interacts with the V domain of HIgR͞PRR1 contains the antigenic site Ia, in agreement with the finding that mAbs to this site block binding of PRR1(HveC) to virions (27) , and that the gD region interacting with HIgR͞PRR1 does not exactly overlap with that recognized by HveA, which recognizes antigenic sites Ib and VII, but not Ia (26) .
Current data provide several lines of evidence that the V domain of HIgR͞PRR1 contains the major functional region involved in and sufficient for HSV-1 entry into cells and for physical interaction with gD. Notwithstanding this, we noticed a reduction in the efficiency of the V domain relative to the full-length molecule to interact with virions and with gD, particularly evident in the lower ability of V-TM(PRR1) to mediate susceptibility to HSV-1 infection. Several explanations may account for these reductions, which remain to be investigated further. Thus, for example, the CC domains may provide a spacer that enhances accessibility of virions to the V domain, and͞or the CC domains may form a scaffolding for a conformation of the V domain suitable to its interaction with virions and gD, as proposed for PVR (34) . Alternatively, homo-or heterooligomer formation or association with additional cell surface proteins may be altered as a consequence of the removal of the CC domains. Further yet, the CC domains may have secondary sites that bind gD or may be able to bind the additional glycoproteins, gB and gH͞gL, that participate in HSV-1 entry process and thus recruit them to the fusion complex. Consistent with current findings, in the case of poliovirus or HIV interaction with engineered forms of PVR or CD4, respectively, the N-terminal domain was sufficient to render cells susceptible to infection although the virus yields were reduced (32) (33) (34) . In addition, in the case of poliovirus and rhinovirus receptors, the functional domains need to have a certain degree of flexibility, which may be provided by the CC and interdomain portions, as their cognate binding sites are located in a canyon embedded in the capsid.
Resolution of the interaction at the molecular level of HSV-1 with its bona fide receptors has two major implications. On one hand, it is instrumental to define the interaction between gD and HIgR͞PRR1 in terms of minimal size of the functional domain, structural requirements, key residues, etc. In the present study the major functional region of HIgR͞ PRR1 with HSV-1 entry activity able to physically interact with the viral gD was narrowed to a region of about 114 aa residues. Ultimately, these studies could lead to a model that would allow critical tests of the fusion event between HSV-1 envelope and the plasma membranes and the mode of recruitment of the other viral glycoproteins involved in the process. On another hand, analyses of the interaction of gD with the functional regions of its receptor may lead to practical applications. Infections with HSV-1 are highly prevalent among humans. Pathologic manifestations vary from mucocutaneous lesions of the mouth, face, eyes, or genitals, to involvement of central nervous system, resulting sometimes in encephalitis (see ref. 37) . The identification that a major functional domain of HIgR͞PRR1 is encoded in the V domain coupled with the demonstration that this domain is sufficient for physical binding to gD and to compete with virion infectivity may provide a basis for the future development of a novel class of anti-HSV agents designed specifically to block HSV-1 infection.
